Viatris (VTRS) Total Non-Current Liabilities (2019 - 2026)
Viatris (VTRS) posted Total Non-Current Liabilities of $18.8 billion for Q2 2026, down 6.64% on a QoQ basis from $20.1 billion in Q1 2026, and down 10.69% year-over-year from $21.0 billion in Q2 2025.
Analysis
Viatris (VTRS) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
Viatris has reported Total Non-Current Liabilities for 8 years, with the latest figure at $18.8 billion in Q2 2026.
- On a quarterly basis, Total Non-Current Liabilities fell 10.69% year-over-year to $18.8 billion in Q2 2026; TTM through Jun 2026 was $18.8 billion, a 10.69% decrease from a year earlier, with the FY2025 full-year figure at $20.5 billion, down 2.19% from the prior year.
- Total Non-Current Liabilities was $18.8 billion for Q2 2026 at Viatris, down from $20.1 billion in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $31.1 billion in Q1 2022, with the low at $18.8 billion in Q2 2026.
- Average Total Non-Current Liabilities over 5 years is $24.2 billion, with a median of $24.8 billion recorded in 2024.
- The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities slipped 18.58% in 2024, then fell 2.19% in 2025.
- Over 5 years, Total Non-Current Liabilities stood at $27.2 billion in 2022, then fell by 5.49% to $25.7 billion in 2023, then retreated by 18.58% to $20.9 billion in 2024, then decreased by 2.19% to $20.5 billion in 2025, then slipped by 8.33% to $18.8 billion in 2026.
- The last three Total Non-Current Liabilities figures came in at $18.8 billion (Q2 2026), $20.1 billion (Q1 2026), and $20.5 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | 16.45 Bn |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | 18.76 Bn |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | 1.29 Mn |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | 2.78 Bn |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | 24.86 Bn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | 1.45 Bn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 881.37 Mn |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | 946.17 Mn |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | 20.92 Mn |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | 1.86 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 18.76 Bn |
| Mar 31, 2026 | 20.09 Bn |
| Dec 31, 2025 | 20.47 Bn |
| Sep 30, 2025 | 20.88 Bn |
| Jun 30, 2025 | 21.01 Bn |
| Mar 31, 2025 | 20.98 Bn |
| Dec 31, 2024 | 20.93 Bn |
| Sep 30, 2024 | 23.09 Bn |
| Jun 30, 2024 | 24.01 Bn |
| Mar 31, 2024 | 25.50 Bn |
| Dec 31, 2023 | 25.70 Bn |
| Sep 30, 2023 | 26.23 Bn |
| Jun 30, 2023 | 26.18 Bn |
| Mar 31, 2023 | 26.64 Bn |
| Dec 31, 2022 | 27.19 Bn |
| Sep 30, 2022 | 27.74 Bn |
| Jun 30, 2022 | 29.51 Bn |
| Mar 31, 2022 | 31.13 Bn |
| Sep 30, 2021 | 32.88 Bn |
| Jun 30, 2021 | 34.54 Bn |